Assays for human T cell lymphotrophic virus types I and II

Details Assays for human T cell lymphotrophic virus types I and II Assays for human T cell lymphotrophic virus types I and II

2000-04-06

2004-11-30

Fredman, Jeffrey (Department: 1637)

Chemistry: molecular biology and microbiology

Measuring or testing process involving enzymes or...

Involving nucleic acid

C435S007100, C435S007920, C435S091100, C435S091200, C530S350000

Reexamination Certificate

active

06824977

ABSTRACT:

FIELD OF THE INVENTION
The present invention is directed to methods for screening for HTLV-I and HTLV-II.
BACKGROUND OF THE INVENTION
Human T cell lymphotropic virus type I (HTLV-I) is known to be the cause of neoplastic diseases, such as adult T cell leukemia/lymphoma (ATLL), as well as of fatal demyelinating disorders, such as tropical spastic paraparesis and HTLV-I-associated myelopathy (TSP/HAM) (Gessain et al, 1985; Osame et al, 1987), which are non-neoplastic inflammatory/autoimmune conditions. While the majority of affected patients have antibodies, more recent studies have identified HTLV-I antibody negative cases of ATLL (Poiesz et al, 1980; Hinuma et al, 1981; Miyoshi et al, 1981) and TSP/HAM cases occur (Korber et al, 1991; Ohshima et al, 1991; Ramirez et al, 1998). Transmission of the virus is mediated by transfusion of virus-harboring leukocytes in blood and breast milk, as well as sexually, from male to female. Perinatal transmission occurs also in 5% of non-breast-fed children of healthy virus-carrying mothers (Gessain et al, 1985). In contrast to HIV, free virus particles do not seem to be infectious. However, following transfusion of cellular blood components harboring HTLV-I, 44 to 64% of recipients seroconvert (Osame et al, 1986; Blattner, 1989; Yoshida, 1994. For this reason, all blood used for transfusion in the USA has been screened for antibodies to the structural proteins of HTLV since 1988. This is done using ELISA or Western blot techniques using viral lysates which identify antibodies to the structural proteins of the virus, such as HTLV-I/II core (gag) protein p24 and envelope (Env) proteins gp46, gp64/68.
On the basis of the above testing, the prevalence of HTLV-I infection among Americans without obvious risk factors, such as being from an endemic region or intravenous drug abuse, has been estimated to be about 0.016% (Lee et al, 1991). It may be as high as 0.1% in some locations (Williams et al, 1988). One suspects that infection with HTLV-I infection among Caucasian Americans may be higher than determined by routinely used methods in light of studies on cutaneous T cell lymphoma mycosis fungoides (MF) (Zucker-Franklin et al, 1991; Pancake et al, 1995). MF patients usually do not have antibodies to the structural proteins of the virus, but harbor proviral sequences of HTLV-I in their peripheral blood mononuclear cells and skin (Zucker-Franklin, 1991; Pancake et al, 1995; Zucker-Franklin, 1994; Khan et al, 1996). A high percentage of these patients were also shown to have antibodies to HTLV-I Tax (Pancake et al, 1996b), an antigen not included in commercially available HTLV serologic tests.
A study was conducted of healthy relatives of MF patients who were serologically negative for antibodies to HTLV-I when their specimens were tested at a major blood transfusion center (Zucker-Franklin et al, 1997a). Of the first eight individuals tested, six proved to have tax sequences in the PBMCs and antibodies to the Tax antigen by Western blot analysis. Since family studies of a relatively rare disease manifested mostly in middle-aged and elderly individuals are time-consuming, a more expeditious approach was chosen to determine whether currently used serologic methods are adequate to establish the true prevalence of HTLV infection among blood donors.
Accordingly, a cohort of individuals among whom the prevalence of HTLV infection was known to be high, i.e., known injection drug users (IDUs) was selected for study (Zucker-Franklin et al, 1997b). Matched sera and PBMCs obtained from 81 HIV-negative methadone clinic attendees were tested by routine serologic methods, as well as for tax, pol, and gag proviral sequences by PCR/Southern blot analysis and antibodies to viral structural proteins, as well as to the Tax gene product. Routine serology proved 18/81 (22%) of these specimens to be positive for antibodies to HTLV, which concurred with results obtained by other investigators. On the other hand, 39/81 (48.1%) were found positive for HTLV proviral sequences by biomolecular means, and 42 (51.8%) were positive when both serologic tests and PCR/Southern blot analyses were used. Together, the results of these studies suggested that the prevalence of infection with HTLV, particularly when efforts are made to detect Tax sequences, may be considerably higher than is currently believed.
Food and Drug Administration-approved blood screening assays are available which may be used to detect the presence of HTLV-I antibodies in blood samples. Available screening assays are discussed in CDCP (1988). These assays typically use viral antigenic proteins isolated from mammalian cell cultures which are infected with HTLV-I. Other assays are reported in Sawada et al, U.S. Pat. No. 4,588,681; Essex et al, PCT Publication WO 84/04327; Copeland et al (1986); Saxinger et al (1983); Bodner et al, EPA 1035352; and Hare et al, PCT Publication WO 91/07510, the entire contents of all of which are hereby incorporated by reference.
However, many people infected with HTLV-I or -II have lost the sequences which encode the structural components of the virus. While these individuals have antibodies to Tax, they test negative for antibodies to HTLV by tests which are currently used in blood banks (Zucker-Franklin et al, 1997a; Zucker-Franklin et al, 1997b; Ehrlich, 1989; Shiori, 1993; Pancake, 1996b). Thus, their blood is considered safe for transfusion.
Some of the problems associated with use of HTLV-I proteins derived from infected mammalian cells may be overcome by applying recombinant DNA methods and techniques to develop antigenic polypeptides in non-mammalian host cells.
HTLV-I assays using recombinant antigenic polypeptides have been described. Lal et al (1996) have made antigenic polypeptides. Antigenic polypeptides expressed in
E. coli
transformed with portions of the gag gene may be used in an immunodot assay. The sensitivity of this immunodot assay was described as being comparable to Western blots, and the results were described as being as reliable as radioimmunoassays (Kanner et al, 1986). Itoh et al, in U.S. Pat. No. 4,795,805, disclose another assay using antigenic polypeptides encoded by the gag gene.
WO 91/07510 of Amgen Inc. discloses the use of one or more recombinant polypeptide antigens which are polypeptides encoded by all or part of the env, tax or gag genes of HTLV-I. There is no suggestion therein that the use of any one of these antigens is better than either of the others.
Other HTLV-I derived recombinant antigenic polypeptides have also been used in immunoassays. Cell lysates containing either a 59 kD fusion polypeptide encoded by about half of the env gene and about three-quarters of the tax gene or a single 100 kD fusion polypeptide encoded by gag, env, and tax gene fragments reacted with sera from an HTLV-I infected patient using a Western blot analysis (Kitajima et al, 1988).
A sensitive HTLV-I assay which uses recombinant antigenic polypeptides requires antigens which are readily available and which are immunologically reactive with antibodies found in all or nearly all seropositive individuals. These antigenic polypeptides must be readily purified in order to avoid or eliminate non-specific binding to contaminating host cell proteins by cross-reactive antibodies which may be present in body fluid samples. These antigenic polypeptides must also retain their immunological activity when they are used to prepare immunoassay apparatus which typically involve adsorption of the antigenic polypeptides onto a solid support and contacting the adsorbed polypeptides which various blocking and washing reagents.
It has previously been believed that a sensitive HTLV-I assay requires more than one antigen in a single assay in order to detect individuals exposed to HTLV-I that have different antibody profiles. Hare et al, PCT WO 91/07510, note that for any given seropositive population, individuals exhibit different immunogenic responses to viral antigens, and an assay using only one antigen may not detect all of the exposed individuals. Thus, Hare et al use a single s

Affiliated with

Also associated with

Rating

Assays for human T cell lymphotrophic virus types I and II does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Assays for human T cell lymphotrophic virus types I and II, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Assays for human T cell lymphotrophic virus types I and II will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3327068